Table 2:
Age-standardized cancer incidence and relative risk of cancer among Métis and non-Aboriginal adults, 1992–2009, by sex* and cancer site, Canada
| Cancer site | No. of cases in Métis† | Ethnic group; ASR‡ per 100 000 | Model no.; RR (95% CI) | ||
|---|---|---|---|---|---|
|
|
|
||||
| Non-Aboriginal | Métis | Model 1§ | Model 2¶ | ||
| All sites | 1090 | 514.3 | 546.4 | 1.06 (1.00–1.12) | 1.05 (0.99–1.11) |
|
| |||||
| Men | 570 | 560.7 | 558.2 | 0.99 (0.91–1.07) | 0.97 (0.89–1.06) |
|
| |||||
| Women | 525 | 457.4 | 533.0 | 1.14 (1.04–1.24) | 1.13 (1.04–1.24) |
|
| |||||
| Lung** | 225 | 73.3 | 114.0 | 1.50 (1.32–1.70) | 1.34 (1.18–1.52) |
|
| |||||
| Men | 125 | 89.8 | 125.8 | 1.39 (1.18–1.64) | 1.22 (1.03–1.43) |
|
| |||||
| Women | 95 | 57.5 | 107.8 | 1.67 (1.38–2.03) | 1.56 (1.28–1.89) |
|
| |||||
| Female breast | 165 | 146.0 | 165.2 | 1.12 (0.97–1.30) | 1.18 (1.02–1.37) |
|
| |||||
| Prostate | 145 | 157.3 | 150.2 | 0.96 (0.82–1.11) | 1.00 (0.86–1.17) |
|
| |||||
| Colorectal | 115 | 63.9 | 56.4 | 0.90 (0.76–1.08) | 0.90 (0.75–1.06) |
|
| |||||
| Men | 75 | 75.4 | 74.3 | 1.02 (0.83–1.26) | 1.03 (0.83–1.26) |
|
| |||||
| Women | 35 | 50.3 | 37.0 | 0.71 (0.52–0.97) | 0.69 (0.50–0.95) |
|
| |||||
| Non-Hodgkin lymphoma | 40 | 26.1 | 21.0 | 0.85 (0.65–1.12) | 0.86 (0.66–1.13) |
|
| |||||
| Kidney | 35 | 13.9 | 17.5 | 1.26 (0.93–1.71) | 1.23 (0.91–1.67) |
|
| |||||
| Stomach | 30 | 10.8 | 15.5 | 1.44 (1.04–2.01) | 1.37 (0.98–1.90) |
|
| |||||
| Bladder | 30 | 16.9 | 14.1 | 0.80 (0.57–1.11) | 0.79 (0.56–1.10) |
|
| |||||
| Oral and pharynx | 25 | 11.9 | 12.9 | 0.98 (0.68–1.41) | 0.88 (0.61–1.27) |
|
| |||||
| Pancreas | 25 | 11.6 | 12.2 | 1.04 (0.71–1.53) | 1.03 (0.70–1.51) |
|
| |||||
| Uterus | 25 | 28.4 | 25.7 | 0.89 (0.62–1.28) | 0.91 (0.64–1.32) |
|
| |||||
| Cervix | 25 | 11.0 | 22.9 | 2.05 (1.37–3.06) | 1.84 (1.23–2.76) |
|
| |||||
| Ovary | 25 | 16.5 | 22.6 | 1.38 (0.94–2.03) | 1.41 (0.96–2.08) |
|
| |||||
| Liver | 15 | 3.7 | 8.2 | 2.01 (1.25–3.25) | 2.09 (1.30–3.38) |
|
| |||||
| Larynx | 15 | 4.2 | 8.1 | 1.82 (1.17–2.83) | 1.60 (1.03–2.48) |
|
| |||||
| Thyroid | 15 | 10.3 | 6.6 | 0.69 (0.42–1.13) | 0.76 (0.47–1.24) |
|
| |||||
| Melanoma | 10 | 16.8 | 6.5 | 0.49 (0.32–0.76) | 0.54 (0.35–0.84) |
|
| |||||
| Brain and CNS | 10 | 8.5 | 4.6 | 0.55 (0.30–1.03) | 0.57 (0.31–1.06) |
|
| |||||
| Leukemia | 5 | 7.4 | 3.2 | 0.60 (0.34–0.96) | 0.59 (0.37–0.94) |
|
| |||||
| Gallbladder | 5 | 1.3 | 2.8 | 2.50 (1.19–5.27) | 2.35 (1.12–4.96) |
Note: ASR = age-standardized rate, CI = confidence interval, CNS = central nervous system, RR = relative risk.
Breakdown by sex for all sites and the top 4 incident cancer sites (lung, female breast, prostate, colorectal).
According to Statistics Canada protocols, the counts in this table, including totals, are randomly rounded either up or down to a multiple of 5. When data are summed or grouped, the total value may not match the individual values because totals and subtotals are rounded independently.
Standardized to the World Standard Population.23
With adjustment for age and sex (if applicable) only.
With adjustment for age, sex (if applicable), income and rurality.
Lung cancer = cancers of the lung and bronchus.